Minerva Neurosciences (NASDAQ:NERV) Rating Increased to Sell at Wall Street Zen

Minerva Neurosciences (NASDAQ:NERV) was upgraded by analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

A number of other research analysts have also recently commented on NERV. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday. HC Wainwright lowered their price objective on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $4.00.

Minerva Neurosciences Trading Up 2.7%

NERV opened at $3.84 on Friday. The firm’s fifty day moving average price is $3.55 and its two-hundred day moving average price is $2.50. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). On average, sell-side analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Apella Capital LLC lifted its holdings in Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,314 shares of the biopharmaceutical company’s stock after buying an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 at the end of the most recent quarter. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.